115 related articles for article (PubMed ID: 37356327)
1. Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.
Leone JP; Graham N; Leone J; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Vallejo CT; Winer EP; Lin NU; Tayob N
Eur J Cancer; 2023 Aug; 189():112930. PubMed ID: 37356327
[TBL] [Abstract][Full Text] [Related]
2. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool.
Leone JP; Graham N; Tolaney SM; Leone BA; Freedman RA; Hassett MJ; Leone J; Vallejo CT; Winer EP; Lin NU; Tayob N
Eur J Cancer; 2022 Sep; 173():20-29. PubMed ID: 35841843
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with late risks of breast cancer-specific mortality in the SEER registry.
Leone JP; Vallejo CT; Hassett MJ; Leone J; Graham N; Tayob N; Freedman RA; Tolaney SM; Leone BA; Winer EP; Lin NU
Breast Cancer Res Treat; 2021 Aug; 189(1):203-212. PubMed ID: 33893907
[TBL] [Abstract][Full Text] [Related]
4. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
5. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry.
Leone JP; Leone BA; Tayob N; Hassett MJ; Leone J; Freedman RA; Tolaney SM; Winer EP; Vallejo CT; Lin NU
Breast Cancer Res Treat; 2021 Jun; 187(3):843-852. PubMed ID: 33590387
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
[TBL] [Abstract][Full Text] [Related]
7. Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
Leone J; Hassett MJ; Freedman RA; Tolaney SM; Graham N; Tayob N; Vallejo CT; Winer EP; Lin NU; Leone JP
JAMA Oncol; 2024 Apr; 10(4):508-515. PubMed ID: 38421673
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant treatment and survival in older women with triple negative breast cancer: A Surveillance, Epidemiology, and End Results analysis.
Kozak MM; Xiang M; Pollom EL; Horst KC
Breast J; 2019 May; 25(3):469-473. PubMed ID: 30925635
[TBL] [Abstract][Full Text] [Related]
9. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
Hanrahan EO; Gonzalez-Angulo AM; Giordano SH; Rouzier R; Broglio KR; Hortobagyi GN; Valero V
J Clin Oncol; 2007 Nov; 25(31):4952-60. PubMed ID: 17971593
[TBL] [Abstract][Full Text] [Related]
10. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
Wu W; Wu M; Peng G; Shi D; Zhang J
Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
[TBL] [Abstract][Full Text] [Related]
11. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
12. Exploration of prognostic factors and the value of adjuvant chemotherapy in T1a,bN0M0 triple-negative breast cancer: a prospective cohort study based on the SEER database.
Wu J; Lv M; Yuan P; Ma Y; Tian P; Li L; Wang C; Lu Z; Yan M; Chen X; Liu Z
Gland Surg; 2022 Aug; 11(8):1341-1355. PubMed ID: 36082084
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer-Specific Mortality in Small-Sized Tumor with Stage IV Breast Cancer: A Population-Based Study.
Zheng YZ; Wang XM; Fan L; Shao ZM
Oncologist; 2021 Feb; 26(2):e241-e250. PubMed ID: 33075188
[TBL] [Abstract][Full Text] [Related]
14. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Liu YR; Jiang YZ; Yu KD; Shao ZM
Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
[TBL] [Abstract][Full Text] [Related]
15. Evaluating overall survival and competing risks of survival in patients with early-stage breast cancer using a comprehensive nomogram.
Xu YB; Liu H; Cao QH; Ji JL; Dong RR; Xu D
Cancer Med; 2020 Jun; 9(12):4095-4106. PubMed ID: 32314546
[TBL] [Abstract][Full Text] [Related]
16. The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study.
Bao J; Yu KD; Jiang YZ; Shao ZM; Di GH
PLoS One; 2014; 9(4):e94815. PubMed ID: 24740002
[TBL] [Abstract][Full Text] [Related]
17. The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis.
Johnson HM; Irish W; Vohra NA; Wong JH
Breast Cancer Res Treat; 2019 Aug; 177(1):155-164. PubMed ID: 31127469
[TBL] [Abstract][Full Text] [Related]
18. Neighborhood Disadvantage, African Genetic Ancestry, Cancer Subtype, and Mortality Among Breast Cancer Survivors.
Iyer HS; Zeinomar N; Omilian AR; Perlstein M; Davis MB; Omene CO; Pawlish K; Demissie K; Hong CC; Yao S; Ambrosone CB; Bandera EV; Qin B
JAMA Netw Open; 2023 Aug; 6(8):e2331295. PubMed ID: 37647068
[TBL] [Abstract][Full Text] [Related]
19. Quantifying the relationship between age at diagnosis and breast cancer-specific mortality.
Johnson HM; Irish W; Muzaffar M; Vohra NA; Wong JH
Breast Cancer Res Treat; 2019 Oct; 177(3):713-722. PubMed ID: 31297648
[TBL] [Abstract][Full Text] [Related]
20. Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits.
Chang Q; Fan L; Li M; Liu L
Medicine (Baltimore); 2023 Feb; 102(8):e33059. PubMed ID: 36827041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
